Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $303M | $311M | $362M | $375M | $382M | $329M | $336M | $346M | $354M | $342M |
| Revenue growth | — | 2.8% | 16.5% | 3.5% | 1.8% | -13.7% | 2.0% | 3.0% | 2.3% | -3.3% |
| Gross profit | $130M | $125M | $141M | $141M | $138M | $124M | $122M | $128M | $132M | $123M |
| Gross margin | 43.1% | 40.1% | 39.0% | 37.5% | 36.2% | 37.5% | 36.4% | 37.0% | 37.4% | 36.0% |
| Operating income | -$3.31M | -$12.2M | -$3.18M | -$31.8M | -$19.9M | -$37.4M | -$31.5M | -$4.74M | -$124M | $3.30M |
| Operating margin | -1.1% | -3.9% | -0.9% | -8.5% | -5.2% | -11.4% | -9.4% | -1.4% | -34.9% | 1.0% |
| Net income | -$21.0M | -$42.7M | -$53.0M | -$88.3M | -$75.5M | -$85.4M | -$79.6M | -$72.4M | -$190M | -$57.7M |
| Net margin | -6.9% | -13.7% | -14.6% | -23.6% | -19.8% | -25.9% | -23.7% | -20.9% | -53.8% | -16.9% |
| EPS (diluted) | -$0.24 | -$0.47 | -$0.56 | -$0.88 | -$0.74 | -$0.82 | -$3.30 | -$3.04 | -$7.19 | -$2.51 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $78.7M | $64.0M | $54.2M | $47.4M | $41.8M | $38.9M | $28.3M | $21.6M | -$79.8M | $6.95M |
| Capital expenditures | $7.48M | $8.28M | $12.9M | $16.7M | — | — | — | — | — | — |
| Free cash flow | $71.2M | $55.7M | $41.2M | $30.7M | — | — | — | — | — | — |
| Share buybacks | $12.2M | $33.6M | $14.2M | $21.1M | $10.5M | $0.00 | $0.00 | — | — | — |
| Dividends paid | $75.4M | $76.7M | $55.3M | $51.4M | $31.4M | $0.00 | $0.00 | — | — | — |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $29.2M | $94.2M | $77.3M | $95.7M | $72.4M | $59.7M | $53.7M | $46.4M | $21.7M | $57.6M |
| Total assets | $2.19B | $2.37B | $2.38B | $2.33B | $2.29B | $2.21B | $2.18B | $2.15B | $1.95B | $1.71B |
| Total liabilities | $689M | $1.02B | $1.14B | $1.22B | $1.33B | $1.17B | $1.18B | $1.24B | $1.26B | $1.11B |
| Shareholders' equity | $1.50B | $1.35B | $1.23B | $1.10B | $957M | $1.03B | $993M | $894M | $685M | $600M |
| Retained earnings | -$487M | -$665M | -$804M | -$971M | -$1.11B | -$1.28B | -$1.46B | — | — | — |
| Shares (wtd avg diluted) | 89.4M | 91.0M | 92.0M | 100M | 106M | 113M | 28.3M | 28.3M | 28.3M | 28.3M |
Every figure is extracted from National Healthcare Properties, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.